期刊
LUPUS
卷 21, 期 2, 页码 168-174出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203311429554
关键词
antiphospholipid antibodies; influenza; systemic lupus erythematosus; vaccine
类别
资金
- Rheuminations, Inc.
- NIAMS
- NIAID
- NCRR [P30 RR031152, P30 AR053483, HHSN266200500026C, U19A1082714]
Background: Antiphospholipid syndrome is characterized by autoantibodies against cardiolipins (aCL), lupus anticoagulant, and independent beta 2- glycoprotein (beta 2GPI). Controversy exists as to whether vaccination triggers the development of antiphospholipid antibodies (aPL) in patients with systemic lupus erythematosus (SLE). Methods: Patients with SLE (101) and matched controls (101) were enrolled from 2005-2009 and received seasonal influenza vaccinations. Sera were tested by ELISA for aCL at baseline, 2, 6, and 12 weeks after vaccination. Vaccine responses were ranked according to an overall anti-influenza antibody response index. Individuals with positive aCL were further tested for beta 2GPI antibodies. Results: Patients with SLE and healthy controls can develop new-onset aCL post vaccination, although at rates which do not differ between patients and controls (12/101 cases and 7/101 controls, OR 1.81, p = 0.34). New-onset moderate aCL are slightly enriched in African American SLE patients (5/36 cases; p = 0.094). The optical density measurements for aCL reactivity in patients were significantly higher than baseline at 2 weeks (p < 0.05), 6 weeks (p < 0.05), and 12 weeks (p < 0.05) post vaccination. No new beta 2GPI antibodies were detected among patients with new aCL reactivity. Vaccine response was not different between patients with and without new-onset aCL reactivity (p = 0.43). Conclusions: This study shows transient increases in aCL, but not anti-beta 2GPI responses, after influenza vaccination. Lupus (2012) 21, 168-174.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据